Clinical trial NCT04565795: Safety and Device Performance of the Uriprene® Degradable Temporary Ureteral Stent Following Uncomplicated Ureteroscopy
Official title: URIPRENE: Clinical Study to Evaluate the Safety and Device Performance of the ADVA-Tec Uriprene® Degradable Temporary Ureteral Stent Following Uncomplicated Ureteroscopy
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Ureteral Diseases
Keywords: ureteral stent
Lead sponsor: Adva-Tec
Sponsor class: INDUSTRY
Collaborators: name: Northwest Clinical Research Group
First posted: 2020-09-25
Enrollment: 87
Sex: ALL
Minimum age (years): 21
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Intervention model description: Patients with clinical symptoms consistent with unilateral ureteral or renal stone fragments post-uncomplicated ureteroscopy (UURS).
Primary purpose: TREATMENT

Brief summary: A prospective, multi-center, non-randomized trial to demonstrate safety and device performance of the ADVA-Tec Uriprene® Degradable Temporary Ureteral Stent.

Detailed description: A prospective, multi-center, non-randomized trial to demonstrate safety and device performance of the ADVA-Tec Uriprene® Degradable Temporary Ureteral Stent. The study is intended to assess the safety and efficacy of the Uriprene® Stent by assessing adequate intervention-free drainage during use and the time to complete degradation or the passage of stent fragments/segments from the urinary system by radiological assessment.

Eligibility criteria: Inclusion Criteria:

1. Subjects who are \>21, \<80 years of age; inclusive of males and females.
2. Subjects with unilateral ureteral or renal stones who have undergone a successful, uncomplicated ureteroscopy (UURS).
3. Subjects with asymptomatic, contralateral renal stones in sizes \<4mm WHICH ARE NOT IN THE RENAL PELVIS OR URETER and who have had uncomplicated ureteroscopy (UURS) can be included. If, during the course of treatment of the target ureter with the Uriprene stent the patient's asymptomatic stone becomes symptomatic and requires treatment, the patient can only be managed with standard of care treatment including the use of an approved ureteral stent, if necessary.
4. Subjects with a height and body size able to accommodate a 20, 22, 24, 26, 28, or 30 mm long ureteral stent, as judged by the Investigator.
5. Subjects with the ability to understand the requirements of the study, who have provided written informed consent, and are willing to undergo all follow-up assessments according to the specified schedule.

Exclusion Criteria:

1. Subjects with a history of an anatomical abnormality of the urinary tract.
2. Presence of ureteral fistula.
3. Presence of urothelial cancer, ureteral tumor, or renal tumor.
4. Presence of extrinsic compression of the ureter.
5. Presence of ureteral blockage or stricture.
6. Bladder outlet obstruction or neurogenic bladder.
7. Subjects with known/diagnosed overactive bladder (OAB).
8. Subjects with known/diagnosed urge urinary incontinence (UUI).
9. Subjects with a known, active upper or lower urinary tract infection at the time of stent insertion.
10. Subjects with creatinine level of ˃2.5 mg/dl.
11. Pregnant or lactating women, or women of childbearing potential who do not employ a reliable method of contraception as judged by the Investigator, and/or are not willing to use reliable contraception for the duration of study participation.
12. Impacted ureteral stones still in place and/or incomplete stone fragmentation.
13. Ureteral perforation.
14. Staghorn calculi.
15. Subjects with a solitary kidney.
16. History of bleeding diathesis or currently taking blood thinners such as warfarin (anti- platelet agents are allowed).
17. Contrast allergy that cannot be adequately pre-treated.
18. Subject has known severe psychiatric disorder, substance abuse, or other reason for being unable to follow trial follow-up instructions or unable to reliably complete patient questionnaires.
19. Any condition, in the opinion of the investigator, that would deem a subject as ineligible for treatment with the Uriprene® Stent.
20. Subject has a known significant concomitant illness with a life expectancy of \<1 year.
21. Subject is known to be currently enrolled in another investigational trial.

Primary outcomes:
measure: Primary Effectiveness Endpoint defined as the presence of the stent during the first 48 hours
timeFrame: 48 hours
measure: Primary Safety Endpoint defined as assessment of adverse events through 90 days
timeFrame: 90 days
Secondary outcomes:
measure: Overall Clinical Success
timeFrame: 90 days
measure: Technical success of the device
timeFrame: 90 days
measure: Tolerability of device presence defined as assessment of pain via the Ureteral Stent Symptom Questionnaire (USSQ) and Patient Diary for pain medications.
timeFrame: 90 days
Other outcomes:
Locations:
city: Phoenix
country: United States
facility: Mayo Clinic Arizona
state: Arizona
city: Los Angeles
country: United States
facility: University of California Los Angeles
state: California
city: San Diego
country: United States
facility: University of California San Diego
state: California
city: Gainesville
country: United States
facility: University of Florida
state: Florida
city: Columbus
country: United States
facility: The Ohio State University
state: Ohio
Study officials:
affiliation: Mayo Clinic
name: Mitchell Humphreys, MD
role: PRINCIPAL_INVESTIGATOR
References: